Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Covid19--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19. In addition, Twist Biopharma, a division of Twist Bioscience, will provide custom antibody drug discovery libraries and

Click to view original post